Cancer Forums and News by PhD's


News | Forums Register

Go Back   Cancer Forums and News by PhD's > Cancer Forums and News

Cancer News

Breast
Colon
Kidney
Leukemia
Liver
Lung
Melanoma
Mesothelioma
Myeloma
Neck
Pancreatic
Prostate


Cancer Review

Breast
Colon
Kidney
Leukemia
Liver
Lung
Melanoma
Mesothelioma
Myeloma
Pancreatic
Prostate


 
Top-Line Phase 2 Clinical Trial Results of Glufosfamide for Treatment of Pancreatic Cancer
By Dross at 2006-12-30 04:25
Top-Line Phase 2 Clinical Trial Results of Glufosfamide for Treatment of Pancreatic Cancer

 

Threshold Pharmaceuticals Announces Top-Line Phase 2 Clinical Trial Results of Glufosfamide for Treatment of Pancreatic Cancer

 

REDWOOD CITY, Calif., Dec. 27 -- Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) , today announced top-line results from the Phase 2 clinical trial of glufosfamide in combination with gemcitabine for the treatment of advanced pancreatic cancer. 21% of patients in the clinical trial had a partial response (including one unconfirmed partial response) and 36% of patients had stable disease. Glufosfamide was generally well tolerated in combination with gemcitabine with no new unexpected adverse events. "We are pleased with these encouraging top-line results and look forward next year to additional six- and twelve-month survival data from this clinical trial," said Barry Selick, Ph.D., Threshold's chief executive officer. "We remain focused on our goal of bringing another treatment option to patients with pancreatic cancer." Phase 2 Clinical Trial Results In the Phase 2 clinical trial, 29 patients were treated, of which 28 patients with pancreatic adenocarcinomaterm previously untreated with chemotherapyterm were evaluated for response. Overall, 5 patients achieved a confirmed partial response and one other patient achieved an unconfirmed partial response. In addition, 10 patients experienced stable disease. Objective response was assessed radiologically after every two cycles of therapy. A partial response is characterized as a decrease in size by 30% of the sum of the longest diameters of target lesions, the absence of progression of all non-target lesions and no new lesions. Preliminary analysis of the safety data in this Phase 2 glufosfamide and gemcitabine combination trial suggests the incidence of treatment-related nephrotoxicity may be slightly higher than what was observed in previous experience with either of these agents used individually. This clinical trial remains ongoing. Final survival and safety results will be reported at the completion of the trial, estimated to occur by the end of the third quarter of 2007.

 

Phase 2 Clinical Trial Design

 

The Phase 2 clinical trial is evaluating patients with locally advanced and/or metastaticterm pancreatic adenocarcinoma previously untreated with chemotherapy. Patients receive the standard dose of gemcitabine plus glufosfamide. In addition to safety, the trial is investigating the efficacy of glufosfamide in combination with gemcitabine as determined by response rate, duration of response, progression-free survival, overall survival, six- and twelve-month survival and change in serum tumor marker levels (CA19-9). Patients in the trial receive the standard dose of gemcitabine (1000mg/m2) weekly for 3 of every 4 weeks and 4500mg/m2 of glufosfamide administered once every 4 weeks. The trial is part of a Phase 1/2 clinical trial, whose Phase 1 results were reported in January 2006 at the ASCO GI Cancers Symposium. The primary objective of the Phase 1 portion of the trial was to evaluate safety and to determine the maximum tolerated dose (MTD) of glufosfamide when administered in combination with gemcitabine. The 19 patients in this portion of the trial received the standard dose of gemcitabine (1000mg/m2) weekly for 3 of every 4 weeks and one of four doses of glufosfamide (1500mg/m2, 2500mg/m2, 3500mg/m2 or 4500mg/m2) administered once every 4 weeks. The maximum tolerated dose was established at 4500mg/m2. No unanticipated adverse events based on previous experience with glufosfamide administered as a single agent were observed.

 



1537 reads

 
Search

sponsored links




Donate


Newsletter



Subscribe to our newsletter to receive info on our site or upcoming clinical trials
Email

Confirm your email address

HTML format
State

Please select the newsletters you want to sign up to:

  • Cancerfocus
    Receive updates from Cancerfocus.
  • Breast
  • Colon
  • Kidney
  • Leukemia
  • Liver
  • Lung
  • Melanoma
  • Mesothelioma
  • Myeloma
  • Neck
  • Pancreatic
  • Prostate





All times are GMT -5. The time now is 05:03 PM.